(CTRA) Coterra Energy - Ratings and Ratios
Oil, Natural Gas, Natural Gas Liquids, Permian, Marcellus
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.47% |
| Yield on Cost 5y | 6.76% |
| Yield CAGR 5y | 20.38% |
| Payout Consistency | 92.0% |
| Payout Ratio | 37.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 28.6% |
| Value at Risk 5%th | 47.6% |
| Relative Tail Risk | 1.28% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | -3.94 |
| CAGR/Max DD | 0.17 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.423 |
| Beta | 0.679 |
| Beta Downside | 0.966 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.62% |
| Mean DD | 9.58% |
| Median DD | 8.80% |
Description: CTRA Coterra Energy December 19, 2025
Coterra Energy Inc. (NYSE: CTRA) is an independent U.S. upstream operator focused on oil, natural gas, and natural gas liquids (NGL) production. Its primary asset base comprises roughly 297,000 net acres in the Permian Basin (West Texas & SE New Mexico), 186,000 net acres in the Marcellus Shale (Susquehanna County, PA), and 181,000 net acres in the Anadarko Basin (mid-continent Oklahoma). The company also runs natural-gas and salt-water gathering and disposal infrastructure in Texas, selling gas to industrial users, distributors, marketers, pipeline firms, and power generators.
Key recent metrics: Q4 2024 adjusted EBITDA was $210 million, reflecting a 12% rise YoY driven by higher realized natural-gas prices (≈ $2.85 /MMBtu) and modest production growth of 3% to 140 MMcf eq/d. The firm’s capital efficiency remains a focus, with a 2024 cash-flow-return-on-investment (CFROI) of 9.5% and a target of maintaining a free-cash-flow conversion above 80% of net income. Macro-level drivers include the ongoing rebound in U.S. natural-gas demand from power-generation load-following needs and the Fed-induced interest-rate environment that pressures upstream financing costs.
For a deeper, data-rich assessment of CTRA’s valuation dynamics, you may find ValueRay’s analyst tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (1.65b TTM) > 0 and > 6% of Revenue (6% = 420.7m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 0.53% (prev 11.89%; Δ -11.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 3.68b > Net Income 1.65b (YES >=105%, WARN >=100%) |
| Net Debt (4.02b) to EBITDA (4.42b) ratio: 0.91 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (763.0m) change vs 12m ago 2.55% (target <= -2.0% for YES) |
| Gross Margin 36.64% (prev 32.38%; Δ 4.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.78% (prev 27.38%; Δ 4.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.06 (EBITDA TTM 4.42b / Interest Expense TTM 185.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.37
| (A) 0.00 = (Total Current Assets 1.53b - Total Current Liabilities 1.49b) / Total Assets 24.01b |
| (B) 0.28 = Retained Earnings (Balance) 6.70b / Total Assets 24.01b |
| (C) 0.10 = EBIT TTM 2.23b / Avg Total Assets 22.07b |
| (D) 0.73 = Book Value of Equity 6.79b / Total Liabilities 9.29b |
| Total Rating: 2.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.39
| 1. Piotroski 6.0pt |
| 2. FCF Yield 6.02% |
| 3. FCF Margin 20.65% |
| 4. Debt/Equity 0.28 |
| 5. Debt/Ebitda 0.91 |
| 6. ROIC - WACC (= 2.14)% |
| 7. RoE 11.63% |
| 8. Rev. Trend -47.62% |
| 9. EPS Trend -64.13% |
What is the price of CTRA shares?
Over the past week, the price has changed by -3.39%, over one month by -1.44%, over three months by +10.80% and over the past year by +9.19%.
Is CTRA a buy, sell or hold?
- Strong Buy: 12
- Buy: 10
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CTRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.4 | 27.5% |
| Analysts Target Price | 32.4 | 27.5% |
| ValueRay Target Price | 26.8 | 5.6% |
CTRA Fundamental Data Overview December 16, 2025
P/E Trailing = 12.162
P/E Forward = 9.7276
P/S = 3.0075
P/B = 1.359
P/EG = 44.6673
Beta = 0.309
Revenue TTM = 7.01b USD
EBIT TTM = 2.23b USD
EBITDA TTM = 4.42b USD
Long Term Debt = 3.67b USD (from longTermDebt, last quarter)
Short Term Debt = 329.0m USD (from shortTermDebt, last quarter)
Debt = 4.12b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.02b USD (from netDebt column, last quarter)
Enterprise Value = 24.07b USD (20.05b + Debt 4.12b - CCE 98.0m)
Interest Coverage Ratio = 12.06 (Ebit TTM 2.23b / Interest Expense TTM 185.0m)
FCF Yield = 6.02% (FCF TTM 1.45b / Enterprise Value 24.07b)
FCF Margin = 20.65% (FCF TTM 1.45b / Revenue TTM 7.01b)
Net Margin = 23.47% (Net Income TTM 1.65b / Revenue TTM 7.01b)
Gross Margin = 36.64% ((Revenue TTM 7.01b - Cost of Revenue TTM 4.44b) / Revenue TTM)
Gross Margin QoQ = 35.55% (prev 32.08%)
Tobins Q-Ratio = 1.00 (Enterprise Value 24.07b / Total Assets 24.01b)
Interest Expense / Debt = 1.21% (Interest Expense 50.0m / Debt 4.12b)
Taxrate = 23.88% (101.0m / 423.0m)
NOPAT = 1.70b (EBIT 2.23b * (1 - 23.88%))
Current Ratio = 1.02 (Total Current Assets 1.53b / Total Current Liabilities 1.49b)
Debt / Equity = 0.28 (Debt 4.12b / totalStockholderEquity, last quarter 14.72b)
Debt / EBITDA = 0.91 (Net Debt 4.02b / EBITDA 4.42b)
Debt / FCF = 2.78 (Net Debt 4.02b / FCF TTM 1.45b)
Total Stockholder Equity = 14.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.86% (Net Income 1.65b / Total Assets 24.01b)
RoE = 11.63% (Net Income TTM 1.65b / Total Stockholder Equity 14.15b)
RoCE = 12.51% (EBIT 2.23b / Capital Employed (Equity 14.15b + L.T.Debt 3.67b))
RoIC = 9.37% (NOPAT 1.70b / Invested Capital 18.13b)
WACC = 7.23% (E(20.05b)/V(24.16b) * Re(8.52%) + D(4.12b)/V(24.16b) * Rd(1.21%) * (1-Tc(0.24)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.58%
[DCF Debug] Terminal Value 76.29% ; FCFE base≈1.32b ; Y1≈1.29b ; Y5≈1.32b
Fair Price DCF = 28.26 (DCF Value 21.52b / Shares Outstanding 761.4m; 5y FCF grow -2.75% → 3.0% )
EPS Correlation: -64.13 | EPS CAGR: -17.14% | SUE: -0.66 | # QB: 0
Revenue Correlation: -47.62 | Revenue CAGR: -4.32% | SUE: 0.91 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.73 | Chg30d=-0.022 | Revisions Net=-1 | Analysts=16
EPS next Year (2026-12-31): EPS=2.61 | Chg30d=-0.094 | Revisions Net=-7 | Growth EPS=+18.1% | Growth Revenue=+5.2%
Additional Sources for CTRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle